Press Release
Business Health

According to a recent report by KDMI, Narcolepsy Drugs Market is anticipated to Boom by 2026

According to a recent report published by KD Market Insights, titled, ” Narcolepsy Drugs Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, and Others) and Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026” Narcolepsy is characterized by several symptoms that include cataplexy, excessive daytime sleepiness, hallucinations, and sleep paralysis. In addition, patients suffering from narcolepsy experience automatic behaviors such as eating, walking, or driving, in a dazed manner. Symptoms differ from patient to patient, and are diagnosed between the ages of 7 and 25. The global narcolepsy drugs market accounted for around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026.

Request for Sample @ https://www.kdmarketinsights.com/sample/5413

Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by this disease. It was estimated that more than 1 in 2,000 people in the U.S. were affected by narcolepsy in 2012. Increase in severity of the disease and rise in the number of people being affected by narcolepsy are some of the key driving factors of the market. Furthermore, the availability of reimbursement for FDA-approved prescription medicines is expected to fuel the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability hinders the market growth. Conversely, increase in the number of programs by various organizations to spread awareness regarding the importance of early narcolepsy diagnosis is anticipated to offer lucrative opportunities for market expansion.

The global narcolepsy drugs market is segmented based on disease type, therapeutics type, and geography. Depending on disease type, the market is categorized into daytime extreme sleepiness, cataplexia, and others. By therapeutics type, it is segregated into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Region wise, the market is examined across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc., Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. have been provided in this report. Product launch and technological advancements are the few strategies adopted by the key players of the global narcolepsy drugs market.

KEY BENEFITS FOR STAKEHOLDERS

– This report highlights the market dynamics to understand the global narcolepsy drugs market and capitalize on the prevailing opportunities.
– Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
– Porter’s five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
– Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.

KEY MARKET SEGMENTS

By Disease Type
– Daytime Extreme Sleepiness
– Cataplexia
– Others

By Therapeutics Type
– Central Nervous System Stimulants
– Tricyclic Antidepressants
– Sodium Oxybate
– Selective Serotonin Reuptake Inhibitor
– Others

By Region

North America
– U.S.
– Canada
– Mexico
Europe
– Germany
– France
– Spain
– Italy
– UK
– Rest of Europe
Asia-Pacific
– Australia
– Japan
– India
– China
– Rest of Asia-Pacific
LAMEA
– Brazil
– Saudi Arabia
– South Africa
– Rest of LAMEA

KEY MARKET PLAYERS

– Ligand Pharmaceuticals
– Addrenex Pharmaceuticals
– Shire Plc.
– Teva Pharmaceutical Industries Ltd.
– Arena Pharmaceuticals
– Jazz Pharmaceuticals Plc.
– Bioprojet
– Graymark Healthcare, Inc.

Browse Full Report With [email protected] https://www.kdmarketinsights.com/product/narcolepsy-drugs-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition and Scope
3.2. Parent Market Overview
3.3. Key Forces Shaping Narcolepsy Drugs Market

3.3.1. Moderate bargaining power of suppliers
3.3.2. Low bargaining power of buyers
3.3.3. Low threat of new entrants
3.3.4. Moderate threat of substitutes
3.3.5. Moderate intensity of rivalry

3.4. Pricing Analysis

3.4.1. Pricing Analysis, By Region, 2018 & 2025

3.5. Market Evolution
3.6. Value Chain Analysis
3.7. Impact of government regulations on global narcolepsy drugs market
3.8. Patent Analysis

3.8.1. By Region
3.8.2. By Applicant

3.9. Market Dynamics

3.9.1. Drivers

3.9.1.1. Increase in global prevalence of narcolepsy
3.9.1.2. Narcolepsy awareness programs and services
3.9.1.3. Presence of reimbursement policies regarding narcolepsy

3.9.2. Restraints

3.9.2.1. Adverse effects and risks related to narcolepsy drugs
3.9.2.2. Delayed diagnosis or misdiagnosis

3.9.3. Opportunity

3.9.3.1. Untapped markets in the developing countries

CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Daytime Extreme Sleepiness

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country

4.3. Cataplexia

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. Other Disease Type

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Central Nervous System Stimulants

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Tricyclic Antidepressants

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Sodium Oxybate

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Selective Serotonin Reuptake Inhibitor

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Other Therapeutic Type

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

Continue…

Check for Discount @ https://www.kdmarketinsights.com/discount/5413

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

Contact Us

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: [email protected]

Website: www.kdmarketinsights.com

Read More News: http://kdmarketinsights.blogspot.com/

https://marketreserachtab.blogspot.com/